ALDER BIOPHARMACEUTICALS INC's ticker is ALDR and the CUSIP is 014339105. A total of 137 filers reported holding ALDER BIOPHARMACEUTICALS INC in Q1 2018. The put-call ratio across all filers is 8.14 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2019 | $155,499,000 | +60.2% | 8,244,896 | 0.0% | 5.20% | +89.5% |
| Q2 2019 | $97,042,000 | -13.8% | 8,244,896 | 0.0% | 2.75% | -16.6% |
| Q1 2019 | $112,543,000 | +68.8% | 8,244,896 | +26.7% | 3.29% | +22.8% |
| Q4 2018 | $66,684,000 | -38.4% | 6,505,766 | 0.0% | 2.68% | -19.5% |
| Q3 2018 | $108,321,000 | +5.4% | 6,505,766 | 0.0% | 3.33% | -4.6% |
| Q2 2018 | $102,791,000 | +24.4% | 6,505,766 | 0.0% | 3.49% | +9.5% |
| Q1 2018 | $82,623,000 | +10.9% | 6,505,766 | 0.0% | 3.19% | -1.5% |
| Q4 2017 | $74,491,000 | -6.1% | 6,505,766 | +0.4% | 3.24% | -17.3% |
| Q3 2017 | $79,340,000 | +211.6% | 6,476,766 | +191.2% | 3.91% | +152.5% |
| Q2 2017 | $25,463,000 | -35.9% | 2,223,811 | +16.4% | 1.55% | -39.9% |
| Q1 2017 | $39,726,000 | +107.5% | 1,909,886 | +107.5% | 2.58% | +56.2% |
| Q4 2016 | $19,147,000 | -16.8% | 920,550 | +31.0% | 1.65% | -9.9% |
| Q3 2016 | $23,022,000 | – | 702,539 | – | 1.83% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Foresite Capital Management III, LLC | 2,942,203 | $36,042,000 | 9.93% |
| Foresite Capital Management II, LLC | 1,043,832 | $12,787,000 | 5.18% |
| Redmile Group, LLC | 6,476,766 | $79,340,000 | 3.91% |
| DAFNA Capital Management LLC | 346,013 | $4,239,000 | 2.63% |
| Cormorant Asset Management, LP | 900,000 | $11,025,000 | 1.95% |
| SENZAR ASSET MANAGEMENT, LLC | 641,170 | $7,854,000 | 1.92% |
| Asymmetry Capital Management, L.P. | 105,228 | $1,289,000 | 1.50% |
| New Leaf Venture Partners, L.L.C. | 171,364 | $2,099,000 | 0.97% |
| EMERALD ADVISERS, LLC | 1,578,477 | $19,336,000 | 0.79% |
| BB BIOTECH AG | 2,266,008 | $27,759,000 | 0.77% |